Requestioning the Role of Prolonged Maintenance Chemotherapy in AML: Randomized Trial by the German AML Cooperative Group Updated.
Reviewer: Mary Kara Bucci, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 10, 2001
Presenter: Thomas Buechner
Presenter's Affiliation: German AML Cooperative Group
Type of Session: Scientific
The German AML Cooperative Group (GAMLCG) has previously reported a survival advantage to 3 years of montly maintenance chemotherapy after standard dose thioguanine/araC/daunorubicin (TAD) vs. no further treatment. This was initially reported in 1985 (JCO 3:1583, 1985). Ten-year update of the previously reported GAMLCG trial of TAD+maintenance vs. TAD alone shows a continued benefit in the maintenance arm, 18% relapse-free survival (RFS) vs 6% in the TAD-alone arm. Based on these results, the GAMLCG performed new randomized trial of 3 years of maintenance chemotherapy vs. no further treatment following a new chemotherapy regimen.
Materials and Methods
The GAMLCG considers the maintenance regimen superior to the no-maintenance arm because of increased chance of cure from the first-line treatment alone. Currently, a trial is underway comparing maintenance chemotherapy as standard therapy vs. autologous bone marrow transplant.
Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.